Drug Trial Radar · NCT03328533
Norepinephrine Versus Phenylephrine Continuous Variable Infusion in Cesarean Delivery
Last checked: Nov 19, 2026Latest source record: Jul 17, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
Nov 10, 2017
Primary completion
May 1, 2018
Study completion May 5, 2018
Sponsor
- Lead sponsor
- Cairo UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Comparison will be conducted between continuous variable infusions of Phenylephrine with starting dose of 0.75 mcg/Kg/min and Norepinephrine Bitartrate with starting dose of 0.1 mcg/Kg/min (with norepinephrine base of 0.05 mcg/Kg/min) for prophylaxis against Post-spinal hypotension during cesarean delivery
Conditions
- Cesarean Section Complications
- Spinal Anesthesia
Interventions
PhenylephrineDrug
Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
NorepinephrineDrug
Norepinephrine bitartrate variable infusion with a starting rate of 0.1 mcg/Kg/min (equivalent to norepinephrine base of 0.05 mcg/Kg/min).
BupivacaineDrug
Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of post-spinal anesthesia hypotension.Time frame: 30 minutes after spinal anesthesia
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cairo University
Cairo, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.